Author(s): McGovern D, Powrie F
Abstract Share this page
Abstract Exciting new results from a genetic study in humans and functional studies in mice have pinpointed interleukin 23 (IL23) and its receptor as a key pathway in the pathogenesis of inflammatory bowel disease (IBD). These findings reveal a hitherto unappreciated role for the IL23 axis in intestinal inflammation and may open new avenues for development of therapeutic strategies in IBD.
This article was published in Gut
and referenced in Journal of Molecular Biomarkers & Diagnosis